DescriptionThese guidelines provide evidence-based recommendations for the clinical treatment of tobacco cessation in adults, addressing a major global public health challenge responsible for over 8 million deaths annually and affecting more than 1.25 billion tobacco users worldwide. They aim to support WHO Member States in strengthening tobacco dependence treatment as a core component of comprehensive tobacco control strategies, particularly in settings where access to cessation services remains limited. Developed in accordance with WHO guideline development standards and informed by systematic reviews and the GRADE approach, the document covers behavioural support, digital interventions, pharmacological treatments and system-level policies to enhance cessation efforts. It provides recommendations on brief advice, intensive counselling, digital tools such as text messaging and artificial intelligence-based interventions, and the use of medications including nicotine replacement therapy, varenicline, bupropion and cytisine. The guidelines also address interventions for smokeless tobacco use and emphasize combining behavioural and pharmacological approaches, alongside considerations of feasibility, cost-effectiveness, equity and implementation in diverse health system contexts. Intended for health-care providers, policy-makers and programme managers, they offer a comprehensive framework to improve access, quality and equity in tobacco cessation services and to support progress towards global health targets. |